Following these transactions, Crockett holds 51,053 shares directly. Additionally, on January 2, he acquired 8,750 RSUs and 21,750 employee stock options, both priced at $0 per share. The RSUs are set to vest over a period starting in January 2026, while the stock options will vest monthly over the next three years. Discover more insights about BCYC and access detailed financial analysis with InvestingPro, which offers additional ProTips and comprehensive research reports. Discover more insights about BCYC and access detailed financial analysis with InvestingPro, which offers additional ProTips and comprehensive research reports.
Following these transactions, Crockett holds 51,053 shares directly. Additionally, on January 2, he acquired 8,750 RSUs and 21,750 employee stock options, both priced at $0 per share. The RSUs are set to vest over a period starting in January 2026, while the stock options will vest monthly over the next three years. Discover more insights about BCYC and access detailed financial analysis with InvestingPro, which offers additional ProTips and comprehensive research reports.
Following these transactions, Crockett holds 51,053 shares directly. Additionally, on January 2, he acquired 8,750 RSUs and 21,750 employee stock options, both priced at $0 per share. The RSUs are set to vest over a period starting in January 2026, while the stock options will vest monthly over the next three years.
In other recent news, Bicycle Therapeutics (NASDAQ:BCYC) has been the subject of various analyst evaluations and financial developments. B.Riley adjusted its price target for Bicycle Therapeutics, reducing it from $28.00 to $17.00, while maintaining a Neutral rating. This revision followed the release of clinical data for zelenectide pevedotin, which did not meet the expectations set by the analyst.
In contrast, H.C. Wainwright revised its price target for Bicycle Therapeutics, reducing it to $33 from the previous $55, while maintaining a Buy rating. The adjustment was influenced by a reassessment of the company's drug development pipeline, particularly the drug candidate zele.
Morgan Stanley (NYSE:MS) maintained its Equalweight rating on Bicycle Therapeutics with a steady price target of $30, highlighting the clarity provided on the Phase 2/3 Duravelo-2 trial timing as a positive development.
Needham retained its Buy rating and $38.00 stock price target for Bicycle Therapeutics, anticipating promising early results for the monotherapy in patients with triple-negative breast cancer. Similarly, Leerink Partners raised the company's price target to $32.00, maintaining an Outperform rating, following the company's third-quarter financial results and pipeline progress.
These are just a few of the recent developments surrounding Bicycle Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.